OncoHost

Precision Diagnostics and Predictive Biomarker Development

Health Tech & Life Sciences
Private
Follow

Company Overview

Snapshot

Founded in April 2017 by Yuval Shaked, OncoHost operates with 11–50 employees. The company has raised $53.4 million across 8 funding rounds from 7 investors. In May 2025, OncoHost was awarded a grant from the EIC Transition Programme to advance precision oncology for patients receiving immunotherapy.

Business overview

OncoHost is a technology company focused on transforming precision medicine to improve patient outcomes in oncology. The company's core product, the PROphet platform, leverages bioinformatics, system biology, proteomic pattern recognition, and machine learning to provide clinicians with actionable clinical insights. This platform helps in selecting optimal therapies and understanding personalized cancer dynamics, primarily addressing treatment resistance in clinical oncology. OncoHost operates within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Pharma & Medical Biotechnology, serving markets in Israel, the United Kingdom, and the United States.

Strategic signal

In March 2026, OncoHost received the 2026 Artificial Intelligence Excellence Award in the Health Category. This recognition validates the company's AI-driven approach to precision oncology and highlights its innovative use of proteomic analysis and machine learning for clinical decision-making, signaling strong technological leadership and potential for market impact.

Log in to access full profile ›

Company Intelligence Q&A

What significant award did OncoHost receive in 2026?
In March 2026, OncoHost won the Artificial Intelligence Excellence Award in the Health Category, recognizing its AI-driven precision oncology solutions.
What grant did OncoHost secure in May 2025?
In May 2025, OncoHost was awarded a grant from the EIC Transition Programme to advance precision oncology for patients receiving immunotherapy.
What was a key development for OncoHost in October 2025?
In October 2025, OncoHost received a New York State laboratory permit, expanding the availability of its PROphet NSCLC precision oncology test.
What research did OncoHost present in October 2025?
In October 2025, OncoHost presented new research on plasma proteomics-based treatment selection in melanoma at ESMO 2025.
What executive appointment did OncoHost announce in November 2024?
In November 2024, OncoHost announced the executive appointment of Ron Andrews as a key leader within the company to further its mission in precision oncology.
Log in to access full profile ›

External links